Literature DB >> 8851616

Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus.

J G Sundelof1, R Thompson, K M White, M W Sasor, L Cama, H Kropp.   

Abstract

Pharmacokinetic parameters were determined for imipenem-cilastatin and a carbapenem antibiotic, L-695,256, active against methicillin-resistant Staphylococcus aureus in rhesus monkeys and a chimpanzee. L-695,256 had larger areas under the concentration-time curve than imipenem-cilastatin (30 +/- 5 versus 24 +/- 1 micrograms.h/ml in the rhesus monkeys and 77 versus 60 micrograms.h/ml in the chimpanzee) and a longer half-life at beta phase (1.2 +/- 0.1 versus 0.6 +/- 0.1 h in the rhesus monkeys and 1.0 versus 0.8 h in the chimpanzee). Resistance to hydrolysis by the renal dehydropeptidase-I allowed L-695,256 to be administered as a single agent.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851616      PMCID: PMC163203     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Antimicrobial resistance of Staphylococcus aureus: genetic basis.

Authors:  B R Lyon; R Skurray
Journal:  Microbiol Rev       Date:  1987-03

2.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

Review 3.  Vancomycin resistance: decoding the molecular logic.

Authors:  C T Walsh
Journal:  Science       Date:  1993-07-16       Impact factor: 47.728

4.  Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus.

Authors:  H de Lencastre; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 5.  Resistance to vancomycin and teicoplanin: an emerging clinical problem.

Authors:  A P Johnson; A H Uttley; N Woodford; R C George
Journal:  Clin Microbiol Rev       Date:  1990-07       Impact factor: 26.132

Review 6.  Thienamycin: development of imipenen-cilastatin.

Authors:  F M Kahan; H Kropp; J G Sundelof; J Birnbaum
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

7.  In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a.

Authors:  H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

8.  Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase.

Authors:  H Kropp; J G Sundelof; R Hajdu; F M Kahan
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

  8 in total
  1 in total

1.  Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates.

Authors:  J G Sundelof; R Hajdu; C J Gill; R Thompson; H Rosen; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.